%0 Journal Article %T Tumor mutational burden as predictive factor of response to immunotherapy %A Gonzalez-Cao, Maria %A Viteri, Santiago %A Karachaliou, Niki %A Aguilar, Andres %A GarcĂ­a-Mosquera, Juan Jose %A Rosell, Rafael %J Translational Lung Cancer Research %D 2018 %B 2018 %9 %! Tumor mutational burden as predictive factor of response to immunotherapy %K %X In May 2018, Hellmann et al . published in Cancer Cell journal a retrospective study analyzing the predictive value of tumor mutational burden (TMB) in 75 non-small cell lung cancer (NSCLC) patients treated with the combination of the anti PD-1 inhibitor nivolumab and the anti CTLA-4 antibody ipilimumab in the Check-Mate 012 study. %U https://tlcr.amegroups.org/article/view/24650 %P S358-S361 %@ 2226-4477